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Abstract
Introduction
Spontaneous bacterial peritonitis (SBP) is the most common life-threatening infection in
patients with ascites due to liver cirrhosis. The infection is most commonly caused by the
bacterium Escherichia coli, commonly referred to as E. coli. Over the past few years, the
incidence of antimicrobial resistance against E. coli has risen drastically, leading to increased
morbidity and mortality.

Methods
This cross-sectional study was conducted to determine the pattern of resistance using
variations of antibiotics against E. coli, to prevent its empirical usage and initiate
an appropriate target antibiotic therapy. The data were collected from May 2017 to October
2017 and included a total of 184 patients. The patients had previously been diagnosed with
chronic liver disease and had presented with E. coli-induced SBP in the medicine wards at Civil
Hospital, Karachi, which is the largest tertiary care hospital in the city. All participants
underwent diagnostic paracentesis, and the ascitic fluid samples were sent to labs for culture
and sensitivity to antibiotics.
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Results
The sample population consisted of 184 participants, of which two-thirds (63.6%; n=117/184) of
the population consisted of males. The mean age of the participants was 47.6±10.7 years. More
than half of the patients had hepatitis C (54.9%; n=101/184) while the remaining were
diagnosed with hepatitis B (45.1%; n=83/184). The ascitic fluid showed varying percentages of
resistance for drugs, with no resistance to imipenem and meropenem while ciprofloxacin
showed the highest resistance in eradicating the bacterium, E. coli. Additionally, a statistical
correlation was tested between drug resistance and factors like age, gender, duration of liver
disease, and duration of ascites. Ciprofloxacin and tetracycline showed a positive correlation
between the resistance of these drugs and the age, gender, and duration of chronic liver disease
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in the participants while trimethoprim/sulfamethoxazole, amoxicillin/clavulanic acid, and
piperacillin/tazobactam showed a positive association with the duration of ascites.

Conclusion
A rapid diligent intervention of cirrhotic patients with complicated ascites is crucial to alleviate
patient mortality. Due to the rising bacterial resistance, primarily, epidemiological patterns
should be assessed and analyzed in our regional hospitals, and then, antibiotics should be
prescribed meticulously.

Categories: Gastroenterology, Infectious Disease, Other
Keywords: escherichia coli (e. coli), antibiotic-resistance, spontaneous bacterial peritonitis, ascites, end
stage liver disease, broad-spectrum antibiotics, paracentesis

Introduction
Ascites is the most common complication in patients with liver cirrhosis or end-stage liver
disease (ESLD), consisting of more than 50% of the cases [1]. Cirrhotic patients, due to ascites,
develop spontaneous bacterial peritonitis (SBP), which is the most common life-threatening
infection of ascitic fluid. Its incidence ranges from 10% to 30% [2] and has several variable
etiologies, with the spreading of bacteria from the gut to the lymph nodes being the most
common underlying pathogenesis [3].
Escherichia coli (E. coli), an intestinal gram-negative bacterium, is known to be a significant
cause of SBP, with non-enterococcus streptococci being the second [4]. According to a study
conducted in 2011, the frequency of E. coli isolated from ascitic fluid in SBP was 66.6%, which
went up by three times from 22% in 2010 [5-6].
SBP has a varying clinical presentation, ranging from being asymptomatic to developing
symptoms like abdominal pain, fever, nausea, and diarrhea. The disease can also lead to
deteriorating symptoms, such as increased confusion and encephalopathy [7]. The diagnosis of
SBP is classically made by looking at the ascitic fluid’s neutrophil count of more than or equal
to 250 cells/mm3 in the presence of a positive culture [8]. However, the culture usually takes
four to five days to confirm the results, leading to a rise in empirical treatment and delayed
targeted therapy. This has caused the mortality rate of SBP to rise drastically despite its early
diagnosis and prompt management [9].
SBP has a staggering mortality rate of 40%-70% in cirrhotic patients and further rises to 80% for
patients who develop septic shock secondary to the infection [10]. Additionally, the constant
neglect in starting definitive therapy has led the mortality rate to rise from 10% to 46% [11-12].
Therefore, there is a crucial need to recognize the antimicrobial resistance pattern of E. coli so
that the targeted antibiotic therapy can be started more readily. Hence, we conducted this study
to determine the frequency of patterns of antibiotic resistance in cases of SBP caused by E. coli
in patients with liver cirrhosis presented in a tertiary care hospital of Karachi, Pakistan.
The practice of empirical treatment has increased the antimicrobial resistance to certain drugs,
making the eradication of the organisms causing SBP a major challenge. A review by Sola et al.
showed the rising failure of conventional treatment options, such as third-generation
cephalosporin (TGC) [13], although local studies have shown no such problems [14].

Materials And Methods
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This cross-sectional study was carried out in Karachi, Pakistan, from May 2017 to October 2017.
The sample population consisted of male and female patients aged 12 years and above. The
patients presented to Civil Hospital Karachi and only patients with previously diagnosed liver
cirrhosis were chosen, irrespective of their precipitating etiology. They had a Child-Pugh score
of B or C and currently presented with the complaint of painful abdominal distention with or
without fever. A non-probability consecutive technique was used to calculate the sample size,
keeping a confidence level of 95% and a margin of error of 7%.
The study only included subjects who presented with symptoms of SBP, which are painful
abdominal distention in the presence or absence of fever and were diagnosed with abdominal
ascites on ultrasound (U/S) abdomen at the time of presentation. Patients only diagnosed with
community-acquired SBP were included. Informed verbal consent was also taken from all
participants before enrolling them in the study.
The diagnosis of chronic liver disease (CLD) was made based on clinical examination and
radiological evidence. Participants with a precipitating etiology other than CLD, such as
nephrotic syndrome and congestive heart failure, were excluded. Moreover, patients who were
diagnosed with SBP and were either on antibiotics or had received antibiotics in the past 10
days, as well as patients who had a poly-microbial growth in the ascitic fluid culture, were also
excluded.
According to the symptoms and the patient’s significant history of liver disease, a high index of
suspicion for ascites complicated with SBP was kept in mind. To confirm the diagnosis of
ascites, patients underwent a departmental U/S, and then they were sent for paracentesis. The
procedure was performed by a qualified postgraduate trainee doctor who followed standard
precautionary guidelines and used all the aseptic techniques.
The procedure was as follows: a total of 20 ml ascitic fluid was collected from each patient for
the detailed report (DR) and culture and sensitivity (CS). Ten ml of ascitic fluid was placed in
blood culture bottles at the bedside using an aseptic technique. Three ml of the sample was
directly cultured on two separate blood agar plates and a chocolate agar plate, after
centrifuging and incubating it at 37°C. The culture plates were monitored daily for the next two
days to identify any significant growth by a qualified microbiologist of a tertiary care hospital
laboratory. Resistance was monitored against various antibiotics: ampicillin/sulbactam,
trimethoprim/ sulfamethoxazole (co-trimoxazole), piperacillin, ciprofloxacin, tetracycline
(doxycycline), amikacin, ofloxacin, ampicillin, amoxicillin/ clavulanic acid, ceftriaxone,
piperacillin/tazobactam, imipenem, and meropenem.
The final results of the ascitic routine examination were made available within a day while the
culture and sensitivity report was made available after one week. Until then, the patients were
treated empirically with broad-spectrum antibiotics, and the response of the therapy was
evaluated using the patients’ symptoms.
Data were entered and analyzed using IBM SPSS Statistics v. 22.0 (Armonk, NY, US). Descriptive
statistics were used to report frequencies and proportions for the categorical responses.
Variables such as gender, age, duration of CLD, and duration of ascites were stratified to see the
effect of these variables on E. coli-mediated resistance against the aforementioned drugs. Ttest was applied for post-stratification, and a p-value of ≤ 0.05 was taken as significant.

Results
The sample population consisted of 184 patients, of which 117 (63.6%) were males and 67
(36.4%) were females, with a mean age of 47.6 ± 10.7 years. Of the 184 participants, about half
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of them were diagnosed with hepatitis B (45.1%; n=83/184) and more than half had hepatitis C
(54.9%; n=101/184). Figure 1 shows the age distribution of the patients.

FIGURE 1: Age distribution of the patients

A confirmed diagnosis was made utilizing the ascitic fluid detailed report while the organism
was identified by performing ascitic fluid culture and sensitivity. The most common organism
on culture was E. coli; hence, the drugs used to treat SBP due to E. coli had various resistance
patterns, which is shown in Table 1. Amongst all the drugs, the highest resistance was seen
with ciprofloxacin and ampicillin, accounting for 38.6% and 37.5%, respectively, while no
resistance was seen with the use of imipenem and meropenem.
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RESISTANCE
ANTIBIOTICS
N/184

%

Ampicillin/Sulbactam

5

2.7%

Trimethoprim/Sulfamethoxazole

20

10.9%

Piperacillin

1

0.5%

Ciprofloxacin

71

38.6%

Tetracycline

52

28.3%

Amikacin

6

3.3%

Ofloxacin

24

13%

Ampicillin

69

37.5%

Amoxicillin/Clavulanic acid

33

17.9%

Ceftriaxone

59

32.1%

Cefotaxime

22

12%

Piperacillin/Tazobactam

12

6.5%

Imipenem

0

0%

Meropenem

0

0%

TABLE 1: Frequency of antibiotic resistance in spontaneous bacterial peritonitis
caused by E. coli in patients with liver cirrhosis

Table 2 shows the frequency of antibiotic resistance in SBP caused by E. coli and its association
with age groups. Ciprofloxacin, tetracycline, and ampicillin expressed the highest resistance in
participants less than 50 years of age. Of which, ciprofloxacin (p=0.023) and tetracycline
(p=0.035) showed a significant correlation between the resistance of these certain drugs and
age groups.
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RESISTANCE
ANTIBIOTICS

Age ≤50 Years (N = 94)

Age >50 Years (N = 90)

P-Value

N (%)

N (%)

Ampicillin/Sulbactam

4(4.3%)

1(1.1%)

0.190

Trimethoprim/Sulfamethoxazole

7(7.4%)

13(14.4%)

0.127

Piperacillin

1(1.1%)

0(0%)

0.085

Ciprofloxacin

44(46.8%)

27(30%)

0.023

Tetracycline

33(35.1%)

19(21.1%)

0.035

Amikacin

3(3.2%)

3(3.3%)

0.99

Ofloxacin

11(11.7%)

13(14.4%)

0.581

Ampicillin

33(35.1%)

36(40%)

0.493

Amoxicillin/Clavulanic acid

12(12.8%)

21(23.3%)

0.062

Ceftriaxone

28(29.8%)

31(34.4%)

0.499

Cefotaxime

10(10.6%)

12(13.3%)

0.573

Piperacillin/Tazobactam

4(4.3%)

8(8.9%)

0.203

Imipenem

0(0%)

0(0%)

NA

Meropenem

0(0%)

0(0%)

NA

TABLE 2: Frequency of antibiotic resistance in spontaneous bacterial peritonitis
caused by E. coli in patients with liver cirrhosis by age groups

Table 3 shows the frequency of antibiotic resistance in SBP caused by E. coli and its association
with gender. The resistance of ciprofloxacin and ampicillin were highest in the male
gender while females had the highest resistance to ampicillin and ceftriaxone. Ciprofloxacin
(p=0.007), tetracycline (p=0.002), and piperacillin/tazobactam (p=0.007) showed a significant
correlation between antibiotic resistance and gender.
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RESISTANCE
P-Value
ANTIBIOTICS

Male n=117

Female n=67

n (%)

n (%)

Ampicillin/Sulbactam

3(2.6%)

2(3%)

0.866

Trimethoprim/Sulfamethoxazole

13(11.1%)

7(10.4%)

0.889

Piperacillin

0(0%)

1(1.5%)

0.364

Ciprofloxacin

54(46.2%)

17(25.4%)

0.007

Tetracycline

28(41.8%)

24(20.5%)

0.002

Amikacin

6(5.1%)

0(0%)

0.059

Ofloxacin

18(15.4%)

6(9%)

0.213

Ampicillin

42(35.9%)

27(40.3%)

0.533

Amoxicillin/Clavulanic acid

22(18.8%)

11(16.4%)

0.685

Ceftriaxone

38(32.5%)

21(31.3%)

0.874

Cefotaxime

17(14.5%)

5(7.5%)

0.155

Piperacillin/Tazobactam

12(10.3%)

0(0%)

0.007

Imipenem

0(0%)

0(0%)

NA

Meropenem

0(0%)

0(0%)

NA

TABLE 3: Frequency of antibiotic resistance in spontaneous bacterial peritonitis
caused by E. coli in patients with liver cirrhosis by gender

Table 4 shows the frequency of antibiotic resistance in SBP caused by E. coli and its association
with the duration of CLD. Several antibiotics had a positive association with the duration of
CLD, where ciprofloxacin and ceftriaxone had the highest resistance in participants with a
duration of less than four years.
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RESISTANCE
PDuration of chronic liver disease ≤ 4

Duration of chronic liver disease > 4

Years n= 128

Years n= 56

n (%)

n (%)

4(3.1%)

1(1.8%)

0.607

Trimethoprim/Sulfamethoxazole 18(14.1%)

2(3.6%)

0.035

Piperacillin

1(0.8%)

0(0%)

0.507

Ciprofloxacin

59(46.1%)

12(21.4%)

0.002

Tetracycline

27(21.1%)

25(44.6%)

0.001

Amikacin

5(3.9%)

1(1.8%)

0.456

Ofloxacin

6(4.7%)

18(32.1%)

0.0005

Ampicillin

39(30.5%)

30(53.6%)

0.003

Amoxicillin/Clavulanic acid

31(24.2%)

2(3.6%)

0.001

Ceftriaxone

47(36.7%)

12(21.4%)

0.041

Cefotaxime

10(7.8%)

12(21.4%)

0.009

Piperacillin/Tazobactam

7(5.5%)

5(8.9%)

0.382

Imipenem

0

0

NA

Meropenem

0

0

NA

ANTIBIOTICS

Ampicillin/Sulbactam

Value

TABLE 4: Frequency of antibiotic resistance in spontaneous bacterial peritonitis
caused by E. coli in patients with liver cirrhosis by duration of chronic liver disease

Table 5 shows the frequency of antibiotic resistance in SBP caused by E. coli and its relation to
the duration of ascites. A high resistant pattern was seen by ciprofloxacin, tetracycline,
ceftriaxone, and ampicillin in both the groups, although a significant correlation was found
between the drugs trimethoprim/sulfamethoxazole (TMP-SMX), amoxicillin/clavulanic acid,
and piperacillin/tazobactam and the duration of ascites.
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RESISTANCE
ANTIBIOTICS

Duration of Ascites ≤ 24 h n= 162

Duration of Ascites > 24 h n= 22

P-Value

n (%)

n (%)

Ampicillin/Sulbactam

3(1.9%)

2(9.1%)

0.109

Trimethoprim/Sulfamethoxazole

13(8%)

7(31.8%)

0.004

Piperacillin

1(0.6%)

0(0%)

0.988

Ciprofloxacin

61(37.7%)

10(45.5%)

0.481

Tetracycline

42(25.9%)

10(45.5%)

0.056

Amikacin

4(2.5%)

2(9.1%)

0.101

Ofloxacin

24(14.8%)

0(0%)

0.053

Ampicillin

62(38.3%)

7(31.8%)

0.557

Amoxicillin/Clavulanic acid

25(15.4%)

8(36.4%)

0.016

Ceftriaxone

49(30.2%)

10(45.5%)

0.152

Cefotaxime

17(10.5%)

5(22.7%)

0.097

Piperacillin/Tazobactam

5(3.1%)

7(31.8%)

0.005

Imipenem

0

0

NA

Meropenem

0

0

NA

TABLE 5: Frequency of antibiotic resistance in spontaneous bacterial peritonitis
caused by E. coli in patients with liver cirrhosis by duration of ascites

Discussion
ESLD carries a global burden for health care, with an estimated 1.2 million mortalities [15-16].
Patients with ESLD pose a weaker immune system and, therefore, have increased exposure to
bacterial attacks, sepsis, and death. Bacterial infections in patients with liver cirrhosis are not
only more frequent but also are responsible for the patient’s deteriorating condition.
SBP, with a prevalence of 8%-27% in patients with cirrhotic ascites, remains amongst the most
significant complication in these patients [17]. Most SBP cases (70%) are caused by gramnegative bacteria, most commonly due to E. coli. As seen similarly to our results, using the
mechanism of enterobacteria trans-locating from the intestinal tract [18].
Past literature has shown a four-fold increase in the mortality of patients reaching almost 58%
in one month and 63% in 12 months [19]. One of the significant reasons for such high mortality
is the rising antimicrobial resistance to antibiotics, including cephalosporin; especially,
cefotaxime, fluoroquinolones, ampicillin/sulbactam, and aminoglycosides [20]. The dire
consequences require prompt diagnosis and appropriate treatment of the infection when
2019 Kirplani et al. Cureus 11(7): e5284. DOI 10.7759/cureus.5284
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managing patients with liver cirrhosis [21].
Moreover, our study showed that 55% of the participants had hepatitis C as the identifiable
cause of their liver disease. This was in accordance with a study done by Toshikuni N et al.,
where 67%-91% of the participants were diagnosed with hepatitis C as the primary etiology of
cirrhosis [22].
Furthermore, our results showed a significantly elevated (38.6%) resistance to ciprofloxacin
against the eradication of E. coli. This is in congruence with a study conducted by Ortiz et al.
where E. coli showed resistant to the use of fluoroquinolones and their failure as a successful
prophylactic agent against SBP [23]. Similarly, another study done in Spain enumerated an
increased probability in the occurrence of SBP in patients who took fluoroquinolones as a
prophylactic agent, concluding intravenous ceftriaxone as a more efficacious drug for SBP
prophylaxis [24]. The reasons demonstrated behind the failure of oral fluoroquinolones were
primarily due to its slow onset and changing the epidemiology of infections [24]. Although,
contrary to our results, a study done in 2017 showed that the intake of oral fluoroquinolones
was successful in preventing and treating SBP [25].
Conversely, studies conducted in Italy and France manifested reduced efficacy with the use of
TGC for SBP with a failure rate of 41% and 57%, respectively [26-27]. However, our study
showed a bacterial resistance of 32.1%, which was far less than the proportion of resistance in
the west.
In the present study, sensitivity to piperacillin-tazobactam, amikacin, ampicillin/sulbactam,
imipenem, and meropenem was better with imipenem and meropenem being 0%, showed by
Lutz P et al. as well [28]. Hence, several studies have recommended their usage as initial
treatment as well as in the prophylaxis of SBP caused by gram-negative organisms [28-29].
In the year 2000, only 1.2% of bacteria were resistant to TGCs. Today, unfortunately, due to the
rising antibiotic resistance, several studies have shown a rise in multidrug-resistant (MDR)
bacterial infections in cirrhotic patients. A study conducted in 2012 discovered a swift rise from
10% to 23% in the prevalence of MDR bacterial infections between 1998 and 2011 [17],
therefore, making it crucial for all medical professionals to meticulously choose antibiotics and
ultimately reducing the aftermaths of the increasing resistant pattern.
Having said that, our study had some limitations that need to be considered. Since only patients
from a single tertiary-care hospital were specifically recruited in the study, the results of this
study cannot be extrapolated to other hospitals. Therefore, further studies should be conducted
in order to determine the generalizability of the results. Additionally, we excluded patients who
were diagnosed with nosocomial SBP. Nevertheless, the findings of our study are vital in
assessing the role of antibiotic resistance in the treatment of ESLD-induced SBP and the need
for targeted therapy in the Pakistani population.

Conclusions
Early and effective antimicrobial treatment is crucial in the management of cirrhotic patients
with superimposed bacterial ascites. The choice of an empirical therapy should be based not
only on the severity and origin of the infection but also on the local microbiological profile. In
the absence of microbiological investigations that demonstrate the presence of gram-negative
MDR bacteria, the carbapenems should not be empirically administered unless there is an
established risk of MDR bacteria. The administration of inappropriate therapy is associated
with increased mortality; hence, the epidemiological patterns of bacterial resistance in our
regional hospitals should be evaluated and monitored.
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interest: In compliance with the ICMJE uniform disclosure form, all authors declare the
following: Payment/services info: All authors have declared that no financial support was
received from any organization for the submitted work. Financial relationships: All authors
have declared that they have no financial relationships at present or within the previous three
years with any organizations that might have an interest in the submitted work. Other
relationships: All authors have declared that there are no other relationships or activities that
could appear to have influenced the submitted work.
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